Johnson & Johnson (JNJ) News Today

Johnson & Johnson (NYSE: JNJ) shares have climbed, supported by stronger-than-expected Q2 results, an upgraded outlook and broad investor interest.

• Positive Sentiment: Posted Q2 EPS of $2.77 versus $2.66 expected and revenue of $23.74 billion, topping estimates and demonstrating solid operational execution. Johnson & Johnson Q2 Earnings and Revenues Top Estimates
• Positive Sentiment: Beat profit estimates and raised full-year sales forecast by about $2 billion, driven by strong Darzalex cancer drug and medical-device sales. Johnson & Johnson beats profit estimates on strong Darzalex, medtech sales
• Positive Sentiment: TD Cowen maintained a Buy rating with a $185 price target, citing the company’s solid Q2 performance and growth prospects. Johnson & Johnson’s Strong Q2 Performance and Growth Prospects Earn a Buy Rating
• Positive Sentiment: Unusual options activity as traders bought over 50,000 call options—40% above average—indicating bullish sentiment. Investors Buy Large Volume of Johnson & Johnson Call Options (NYSE:JNJ)
• Positive Sentiment: Technical analysis highlights a breakout above key resistance, with bullish MACD and stochastic signals supporting further upside. JNJ Technicals & Takeaways After Earnings, Healthcare Reaching Key Levels
• Neutral Sentiment: Featured as one of July’s top dividend stocks, praised for its reliable “Dividend King” status and current yield around 3.35%. Want Steady Income? 3 Top Dividend Stocks for July 2025
• Neutral Sentiment: Declared a quarterly dividend of $1.30 per share (3.35% yield), maintaining its long track record of payouts. Johnson & Johnson (NYSE:JNJ) Declares $1.30 Quarterly Dividend
• Neutral Sentiment: Released FY 2025 guidance with EPS of $10.80–$10.90 and revenue of $93.2–$93.6 billion, broadly in line with consensus. Johnson & Johnson (NYSE:JNJ) Releases FY 2025 Earnings Guidance
• Neutral Sentiment: Included in medical-stock watchlists for its defensive healthcare exposure. Medical Stocks To Add to Your Watchlist - July 16th
• Negative Sentiment: Jim Cramer noted ongoing talc lawsuits remain an overhang, potentially dampening sentiment. Jim Cramer Notes Johnson & Johnson Talc Lawsuits “Puts a Damper on the Stock”
• Negative Sentiment: Pre-earnings previews highlighted tariff risks and MedTech softness, which had weighed on sentiment ahead of results. Johnson & Johnson Q2 Preview: Focus on tariff threat, MedTech softness
• Negative Sentiment: Some analysts cautioned that JNJ’s dividend payout ratio remains elevated, posing sustainability questions despite the high yield. Build Stability and Income With 3 Overlooked Dividend Leaders